Drug name | Target | Target id | Disease area | Indication |
---|---|---|---|---|
Auranofin | NFkB pathway | IKBKB, PRDX5, TRPA1 | Rheumatology | Rheumatoid arthritis |
BAY-11–7082 | NFkB pathway | RELA | Not available | Not available |
Betulinic-acid | Apoptosis stimulant NFkB pathway inhibitor | GPBAR1 | Not available | Not available |
Bindarit | NFkB pathway | CCL2, CCL7, CCL8 | Not available | Not available |
Bortezomib * | NFkB pathway Proteasome | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | Hematologic malignancy | Multiple myeloma MCL |
Carfilzomib | Proteasome | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | Hematologic malignancy | Multiple myeloma |
Ceritinib | ALK tyrosine kinase | ALK, FLT3, IGF1R, INSR, TSSK1B | Oncology | NSCLC |
Colchicine | Microtubule organization | GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 | Other | Gout Fever |
Crizotinib * | ALK tyrosine kinase | ALK, MET | Oncology | NSCLC |
Curcumin | Cyclooxygenase Histone acetyltransferase Lipoxygenase NFkB pathway | APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CHRM3, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH | Not available | Not available |
Daunorubicin | RNA synthesis Topoisomerase | TOP2A, TOP2B | Hematologic malignancy | AML ALL |
Delanzomib | Proteasome | CMA1, CTSG, CYP3A4, ELANE | Not available | Not available |
Docetaxel | Tubulin polymerization | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 | Oncology | Breast cancer NSCLC Prostate cancer GAC HNSCC |
Doxorubicin | Topoisomerase | TOP2A | Oncology | ALL AML Wilm’s tumour Breast cancer Ovarian cancer Hodgkin’s lymphoma Bladder cancer Multiple myeloma |
Epirubicin | Topoisomerase | CHD1, TOP2A | Oncology | •Breast cancer |
Erythromycin | NFkB pathway | MLNR | Infectious disease | Listeria Respiratory tract infections Skin infections Syphilis Amebiasis Pelvic inflammatory disease Chlamydia Diphtheria Erythrasma |
Idarubicin | Topoisomerase | TOP2A | Hematologic malignancy | AML |
Mepacrine | Cytokine production NFkB pathway TP53 | PLA2G1B | Infectious disease | Giardiasis |
MG-132 | Proteasome | PSMB1 | Not available | Not available |
Mitoxantrone * | Topoisomerase | TOP2A | Neurology/psychiatry | MS Prostate cancer AML |
NVP-TAE684 | ALK tyrosine kinase | ALK, INSR | Not available | Not available |
Oprozomib | Proteasome | Not available | Not available | |
Paclitaxel | Tubulin polymerization | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 | oncology | Ovarian cancer Breast cancer NSCLC |
parbendazole * | Tubulin polymerization | TUBB | Not available | Not available |
Parthenolide | NFkB pathway | Not available | Not available | Not available |
Ro-106–9920 | NFkB pathway | Not available | Not available | Not available |
Secnidazole | Acetylcholinesterase Microtubule | Not available | Infectious disease | Protozoan infection |
Teniposide | Topoisomerase | TOP2A, TOP2B | Hematologic malignancy | ALL |
Topotecan | Topoisomerase | TOP1, TOP1MT | Oncology | SCLC Cervical cancer |
Ursolic-acid | ATPase NFkB pathway STAT pathway | HSD11B1, PLA2G1B, PTPN1, PYGM | Not available | Not available |
Vinblastine | Microtubule Tubuline polymerization | JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1 | Oncology | Hodgkin’s lymphoma THL Mycosis SLL Testicular carcinoma Kaposi sarcoma |
Secnidazole | Acetylcholinesterase Microtubule | – | Infectious disease | Protozoan infection |
Teniposide | Topoisomerase | TOP2A, TOP2B | Hematologic malignancy | ALL |